Aims The aim of this study was to establish whether pharmacokinetic differences between two pro-drugs of methylprednisolone (MP) are likely to be of clinical significance. Methods This study was a single-blind, randomized, crossover design comparing the bioequivalence of MP released from the pro-drugs Promedrol (MP suleptanate) and Solu-Medrol (MP succinate) after a single 250 mg (MP equivalent) intramuscular injection to 20 healthy male volunteers. Bioequivalence was assessed by conventional pharmacokinetic analysis, by measuring pharmacodynamic responses plus a novel approach using pharmacokinetic/pharmacodynamic modeling. The main measure of pharmacodynamic response was whole blood histamine (WBH), a measure of basophil numbers. Results The MP C max was less for MP suleptanate due to a longer absorption halflife of the prodrug from the intramuscular injection site. The bioavailability of MP was equivalent when based on AUC with a MP suleptanate median 108% of the MP succinate value (90% CI: 102-114%). For C max the MP suleptanate median was 81% of the MP succinate value (90% CI: 75-88%). The t max for MP from MP suleptanate was delayed relative to MP succinate. The median difference was 200% (90% non-parametric CI: 141-283%). The area under the WBH effect-time curve (AUEC) and the maximum response (E max ) were found to be equivalent (90% CI: 98-113% and 93-109% respectively). The maximum changes in other white blood cell counts, blood glucose concentration and the parameters of the pharmacodynamic sigmoid Emax model (EC 50 , E max and c) were also not significantly different between prodrugs. Conclusions MP suleptanate is an acceptable pharmaceutical alternative to MP succinate. The use of both pharmacokinetic and pharmacodynamic response data together gives greater confidence in the conclusions compared with those based only on conventional pharmacokinetic bioequivalence analysis.
data were interpreted together with the PK data, the aim Introduction being to establish whether any pharmacokinetic differences between two pro-drugs of methylprednisolone are likely to The assessment of bioequivalence by using pharmacokinetic and statistical analysis is the accepted method of demonstratbe of clinical significance. Medrol (6-a-methylprednisolone) has been marketed as ing therapeutic equivalence for different formulations of the same drug. This approach obviates the need to conduct an injectable corticosteroid in the form of the sodium succinate ester (Solu-Medrol, Solu-Medrone) for more than clinical efficacy trials in order to demonstrate that a new formulation of an established drug is safe and effective. 20 years. MP succinate is not stable in solution and is therefore marketed as a freeze-dried product that requires However, there are circumstances when the strict criteria of pharmacokinetic bioequivalence may not be readily met, in reconstitution resulting in inconvenience, waste, loss of time in preparation and added cost. Promedrol (methylprednisothis case there is a need to establish whether the differences between the two formulations are likely to be of clinical lone suleptanate: 21-{8-(2-sulphoethyl ) methyl amino}-8-oxo-octanoate, sodium salt) is being developed by the significance. The approach used in this study was to assess comparative bioavailability in terms of conventional pharmUpjohn Company as a pharmaceutical alternative to MP succinate and will be available as a ready to inject solution. acokinetics (PK) and in addition to use pharmacodynamics (PD) responses plus a novel approach using pharmacokinetic/ This study addresses the question of whether MP suleptanate is bioequivalent to MP succinate following a single pharmacodynamic (PK/PD) modeling. The PD and PK/PD intramuscular administration to healthy volunteers. This prednisolone, (ii) by the comparison of methylprednisolone East Lovell Street, Kalamazoo, MI 49007 on 10th September, 1992. All volunteers were provided with information about dependent pharmacodynamic responses and (iii) by comparing the parameters of a pharmacokinetic/pharmacodynamic the study before they agreed to sign an informed consent form. model.
Both MP suleptanate and MP succinate are prodrug esters The subjects reported to the clinic by 19.00 h the day prior to the start of the study (day −1). All subjects fasted that are converted to the active agent, methylprednisolone, by the action of esterase enzymes in vivo. Studies in animals from 23.00 h the night of admission until 12.00 h on day 1, drug dosing was at 08.00 h on day 1. Water was allowed ad and man have shown that the pharmacokinetics of methylprednisolone released from MP suleptanate are similar to libitum throughout the study. The subjects avoided the consumption of alcohol for 24 h preceding drug administhose of MP succinate [1] [2] [3] [4] . However, the rate at which the esterases release methylprednisolone from MP suleptanate tration and for the duration of the study session. During the study period subjects were given a low-fat diet due to the is faster than for MP succinate [3] .
Apart from establishing the safety of the Promedrol potential for plasma lipids to interfere with the drug assays. suleptanate moiety, the critical issue is whether the rate and extent of methylprednisolone bioavailability is sufficiently Drug dosing similar for the two produgs that no clinically significant differences in efficacy or safety results. MP suleptanate and
The 20 volunteers were randomly allocated to two experimental groups. Each group received MP succinate MP succinate are not different formulations of the same chemical entity but chemically different prodrugs of methyland MP suleptanate as a methylprednisolone equivalent dose of 250 mg in a random sequence, separated by a 2 week prednisolone with dissimilar kinetic parameters. Consequently it was likely that bioequivalence in terms of rate wash-out period. Equal numbers of subjects were allocated to each treatment sequence. Two single intramuscular of methylprednisolone appearance in plasma may not be found and therefore a conventional bioequivalence compariinjections were administered into the upper, outer quadrant of the buttocks using a 1.5 inch needle. An evaluation of son of the two prodrugs alone may not be appropriate. For this reason the prodrug pharmacodynamic responses were the site was made to assure that the injection was administered into muscle. measured, in addition to the pharmacokinetics, with the aim of evaluating the pharmacodynamic response-time Promedrol (Upjohn SA Pharmaceutical, Rijksweg 12, B-2870, Puurs, Belgium) was supplied as 180 mg ml −1 relationship and the methylprednisolone concentration-effect relationship, thereby determining the extent to which the solution (100 mg ml −1 methylprednisolone equivalents) and administered as a methylprednisolone equivalent dose of pharmacokinetic differences could be of clinical relevance.
Glucocorticoids play a central role in regulating a number 250 mg. Two 125 mg injections (1.25 ml volume per injection) were made simultaneously, one injection into of physiological processes and the biological effects of these are widespread [5] . In this study, whole blood histamine each buttock for a total volume of 2.5 ml. Solu-Medrol (The Upjohn Company, 7000 Portage Rd, (WBH) was measured at the same times as the drug levels. WBH is a measure of basophil numbers and corticosteroids Kalamazoo, MI 49001, USA) was supplied as the currently marketed formulation and the dose given using the standard such as methylprednisolone inhibit the migration of basophils [6] . A dose dependent decline in circulating basophil solution strength of 62.5 mg ml −1 (methylprednisolone equivalents) and administered as a methylprednisolone numbers occurs following dosing with methylprednisolone providing an index of pharmacodynamic response [7, 8] .
equivalent dose of 250 mg. Two 125 mg injections (2.0 ml −1 volume per injection) were made simultaneously, Using WBH levels the Emax (maximum effect) and AUEC (area under the effect curve) parameters were compared to one injection into each buttock for a total volume of 4.0 ml −1 . examine whether the two prodrugs elicit equivalent responses. A sigmoid Emax pharmacodynamic model [9] linked to the pharmacokinetic model via an effect compartSchedule for blood and urine sampling ment was used to calculate the PK/PD parameters for each prodrug, these parameters were analysed statistically in the Blood was drawn 15 min pre-dose and at the following intervals after dosing; 5, 10, 20 and 45 min and 1.5, 3, 6, 8, same way as the model independent pharmacokinetic and pharmacodynamic parameters. The data for blood glucose 12, 18, 24, and 36 h. For the drug assays 7 ml of the blood was placed in a chilled NaF/EDTA tube and centrifuged in and various blood cell counts were also analysed for significant differences between the treatments. a refrigerated centrifuge as soon as possible (not later than 30 min) and the plasma harvested. Immediately after centrifugation the plasma samples were placed in a freezer Methods at −70°C. For the whole blood histamine assays 3 ml of blood was drawn into a 3 ml heparinized or EDTA tube.
Study design
Sequential urine collections were made over the following time periods relative to the dose; −8 to 0. 0 to 1, 1 to 2, This study was a single-blind, randomized, crossover design in 20 male volunteers comparing the pharmacokinetic and 2 to 4, 4 to 8, 8 to 12, 12 to 18, 18 to 24 and 24 to 36 h. The weight of each volunteer's urine output was measured pharmacodynamic parameters of methylprednisolone released from the prodrugs MP suleptanate and MP at the end of each collection period and a 20 ml aliquot was frozen for the assay of MP succinate and MP suleptanate. succinate. The study was reviewed and approved by the Bronson Methodist Hospital Human Use Committee, 252
To ensure the stability of MP suleptanate and MP succinate on storage 0.20 ml of 1.0 m HClO 4 or 2.0 ml of an aqueous first order input and first order elimination was fitted to the plasma data. Initial estimates of the model parameters were solution of 15 mg ml −1 Na 2 EDTA were added to the aliquots for MP succinate and MP suleptanate respectively. made by an automatic peeling algorithm. These were refined using non-linear weighted least squares regression, with a The samples were stored prior to analysis at −70°C.
weighting of 1/y 2 . [10] . Brief details of the analytical methods are as follows: Plasma and urine samples t max were calculated as described above. The input (absorption) half-life (t 1/2,l1 ) and rate constant (l 1 ) together with (0.5 ml) were spiked with internal standard (fluoromethalone), diluted with 0.5 ml phosphate buffer, and plasma the elimination half-life (t 1/2,l2 ) and rate constant (l 2 ) were obtained from the fitted two exponential model. The total samples processed with solid phase extraction CH cartridges prior to h.p.l.c. separation, u.v. detection at 254 nm was plasma clearance (CL) was estimated from: CL=dose/AUC (Where dose=450 mg for MP suleptanate and 331 mg for used. The coefficient of variation for the assays for the high and low ends of the calibration range respectively were as MP succinate.) The volume of distribution at steady state (V ss ) was calculated using the mean residence time (MRT= follows: Plasma MP 3.1-8.5%, MP succinate 7.9-6.0%, MP suleptanate 5.6-6.9%, assay range MP 0.04-2 mg ml To calculate the Pharmacokinetic and statistical software The plasma concentration vs time data were analyzed using the pharmacokinetic AUEC(0,36 h) for this data the maximum concentration for each profile was noted, each value was then subtracted from software Siphar v 4.0b, SIMED, 9-11 Rue G Enesco, 94008, Creteil, Cedex, France and SAS v 6.04 (SAS Institute this, which had the effect of inverting the profile. The AUEC for these profiles were then calculated by the linear INC, SAS Campus Drive, Cary, NC 27513). SAS v 6.04 was also used to calculate the derived parameters not trapezoidal rule. The t max was the time of the maximum effect, this was the nadir for the blood concentration of produced by Siphar, the cumulative excretion data and the statistical analysis.
histamine. The Emax was maximum observed pharmacological effect, this was the baseline WBH (pre-dose) minus the observed minimum WBH concentration. Pharmacokinetic parameters for methylprednisolone Model independent analysis was used for this data. For each subject the total area under the plasma concentration-time curve
Integrated pharmacokinetic and pharmacodynamic analysis for (AUC) was calculated using the linear trapezoidal rule up whole blood histamine to the last data point AUC(0,t ) and extrapolated from the last data point (C t ) to infinity from AUC(t,2)=C t /l z .
A sigmoid Emax pharmacodynamic model linked to the pharmacokinetic model via an effect compartment [9] was C max was the maximum observed plasma concentration and t max was the time of this observation.The terminal half-life used to calculate the parameters for each prodrug using the pharmacokinetic software Siphar v 4.0b. Initially the (t 1/2,z ) was calculated from t 1/2,z =ln2/l z . The terminal elimination rate constant l z was obtained from non-linear pharmacokinetic parameters for MP were obtained using a single compartment model with first order input and weighted least squares regression with a weighting of 1/y In terms of the extent of bioavailability (AUC) the two tration that produces 50% of the maximum effect), Emax prodrugs were judged to be bioequivalent with a MP (the maximum decrease in WBH) and c (the slope factor suleptanate median AUC of 108% relative to the 100% for for the sigmoid curve). These parameters were analysed the MP succinate reference median (90% confidence interval: statistically in the same way as the model independent 102-114%, log-transformed data). For the rate of bioavailpharmacokinetic and pharmacodynamic parameters. ability (C max ) the MP suleptanate median C max was less than the MP succinate median C max 81% relative to the Statistical analysis and bioequivalence 100% for the MP succinate reference median (90% confidence interval: 75-88%, log-transformed data). The The pharmacokinetic and pharmacodynamic parameters t max for methylprednisolone from MP suleptanate was were analysed for significant differences between the delayed relative to MP succinate. The values were compared treatments for methylprednisolone C max , t max , AUC; histausing non-parametric confidence intervals. The median mine AUEC, Emax and t max and the PK/PD model difference was 200% (90% confidence interval 141-283%) parameters. The normal and log-transformed parameters
The small but significant difference in the observed were analyzed by ANOVA for effect of prodrug, subject, elimination half-life for methylprednisolone between the time period and group sequence. The data were also two pro-drugs (Table 1) is probably caused by the longer examined for evidence of a normal distribution of values elimination half-life of MP suleptanate (Table 2, Figure 1b ). before and after log-transformation using the Procedure UNIVARIATE in SAS. The mean and median parameter values (normal and log-transformed) 90% conventional Plasma and urinary pharmacokinetics of MP succinate and MP confidence intervals were also calculated. Bioequivalence suleptanate criteria [11] were evaluated as follows: methylprednisolone
The plasma concentration-time data for MP succinate and mean parameter value, for MP suleptanate: the 90% MP suleptanate are presented in Figure 1b and the calculated confidence interval to be within 80-120% (80-125% for pharmacokinetic parameters in Table 2 . Following a single log-transformed data) of the methylprednisolone mean intramuscular injection MP succinate had a higher C max , parameter value, for MP succinate. A non-parametric smaller volume of distribution, a shorter elimination halfconfidence interval [12] was used for t max and also for c life and a higher renal clearance than MP suleptanate since this parameter appeared to be neither normally or log ( Table 2 ). The total clearance was very similar for the two normally distributed. A paired t-test was performed on the prodrugs (Table 2 ). However, the major difference between data for glucose, total white cell count, lymphocytes and the two pro-drugs was the rate of absorption from the neutrophils. This comparison was made between the intramuscular injection site. The half-life of the absorption treatments for each time-point for each subjects paired process (t 1/2 =ln2/l 1 ) for MP suleptanate was slower (0.31 h) change from baseline responses ( P<0.05).
than for MP succinate (0.14 h). Figure 2a shows the pharmacodynamic response as assessed A total of 20 male subjects took part in the study ranging by whole blood histamine changes over the 36 h period in age from 18 to 45 years (mean=27±9 years). The post dosing. The pharmacodynamic parameters calculated overall weight ranged from 59.2 to 109.3 kg (mean weight from these data are shown in Table 3 . The basophil count 83.1±11.2 kg).
Results

Comparative pharmacodynamic responses for MP suleptanate and MP succinate Demography of subjects
pharmacodynamic response arising from a single 250 mg (methylprednisolone equivalent) intramuscular dose of MP Pharmacokinetics and bioequivalence for methylprednisolone suleptanate and MP succinate were compared by calculating the 90% confidence intervals for the parameters AUEC, The plasma concentration-time data for methylprednisolone are shown in Figure 1a and the pharmacokinetic parameters Emax and t max for the whole blood histamine. The values are expressed as percentages of the reference mean or calculated from these data are shown in Table 1 cell count (Figure 2b ) was only significantly different between the two prodrugs at 36 h post-dose, but the with a slightly higher value for MP suleptanate as follows:
difference is unlikely to be of clinical significance. MP suleptanate median AUEC of 105% relative to the 100% for the MP succinate reference median (90% confidence interval: 98-113%, log-transformed data). The
Integrated pharmacokinetic and pharmacodynamic analysis for histamine data Emax was slightly less for MP succinate as whole blood histamine follows: MP suleptanate median Emax of 104% relative to the 100% for the MP succinate reference median (90% The sigmoid Emax model described that WBH data very well for both pro-drugs, the adequacy of the fit of the confidence interval: 93-109%, log-transformed data); the model to the data was determined by the residual sum of relative to the 100% for the MP succinate reference median (90% confidence interval: 89-118%, log-transformed data). squares, Akaike information criteria, the coefficient of variation of the parameter estimates and examination of the
The Emax values; MP suleptanate median Emax of 93% relative to the 100% for the MP succinate reference median residuals. Figure 4 shows a typical PK model fit to the MP data and PK/PD model fit to the WBH data for subject (90% confidence interval: 85-101%, log-transformed data).
The c values: MP suleptanate median of 98% relative to the number 20 following the MP suleptanate dose.
For EC 50 , Emax and c there was no significant difference 100% for the MP succinate reference median (90% confidence interval: 84-102%, non-parametric confidence in the response between prodrugs as assessed by ANOVA (P<0.05) for normal or log transformed data. The analysis intervals). The k e0 values were significantly higher for MP suleptanate as follows: MP suleptanate median k e0 of 139% based on confidence intervals gave similar results:
For the WBH data the EC 50 , Emax and c values were relative to the 100% for the MP succinate reference median (90% confidence interval: 126-154%, log-transformed data). equivalent as follows: MP suleptanate median EC 50 103% suleptanate had an equivalent extent of bioavailability (AUC) to that of methylprednisolone released from MP succinate. This result reflects the similar extent of conversion of the (MW 674) compared with MP succinate (MW 497), differences in the volume, pH and concentration of the pro-drugs to methylprednisolone by metabolic action of the esterase enzymes in the liver and other tissues. The small injected dose solution. This is in contrast to the previous unpublished intravenous comparison of MP suleptanate and difference in the AUC values of 7.7% was largely accounted for by the difference in the renal elimination (fe %) of the MP succinate where MP suleptanate produced higher C max values for methylprednisolone than MP succinate, in this two pro-drugs of 7.1%.
The measures of rate of bioavailability (C max and t max ) case the extent of bioavailability was largely determined by the faster rate of metabolic conversion of MP suleptanate to were not as close, the 90% confidence intervals for MP suleptanate were outside the 80-125% range used by most methylprednisolone. regulatory authorities. Methylprednisolone from MP suleptanate was available more slowly and attained the maximum
Comparative pharmacodynamic responses for MP suleptanate concentration at a later time compared to MP succinate.
and MP succinate This observation is likely to be a result of a slower absorption of MP suleptanate from the intramuscular injection site.
The pharmacodynamic measurements were made to assess whether differences in methylprednisolone bioavailability Factors that may have contributed to this are: differences in lipophilicity, the higher molecular weight of MP suleptanate would produce a corresponding difference in pharmacodyn- ANOVA P value=probability of significant difference between treatments for log transformed parameter values. *=Nonparametric confidence intervals.
amic response. The extent of MP suleptanate conversion to simultaneous fitting of prodrug (including input of prodrug from the IM injection site and elimination of intact prodrug methylprednisolone was marginally greater producing a greater AUC, but this was not significantly different. This via the urine), MP and WBH data was undertaken using ADAPT II. This model failed to describe the MP data more finding was reflected in the lack of a significant difference in AUEC for WBH (based on ANOVA and 90% confidence precisely and were overparameterised in the input phase leading to poor PK parameter estimates for MP. However, intervals) for the two prodrugs. The pharmacodynamic measure AUEC is subject to the same problems that AUC these more complex MP inputs did not modify the temporal differences for MP between the prodrugs or the disparate suffers from, i.e. it has no information about the maximum intensity or shape of the response curve. Therefore AUEC estimates of k e0 . should always be considered together with Emax and t max . The maximum response (Emax) for the WBH measurements Conclusions was also not significantly different between the two pro-
The extent (AUC) of methylprednisolone release from MP drugs. This observation was supported by a lack of significant suleptanate was found to be equivalent to MP succinate differences between the prodrugs for the changes in the when given as a single 250 mg methylprednisolone equivalother pharmacodynamic measurements based on white cell ent dose via the intramuscular route. The rate (C max and counts and blood glucose. The EC 50 values were also almost t max ) of methylprednisolone bioavailability was slower for identical for the two prodrugs (Table 4) indicating that MP MP suleptanate due to a longer absorption half-life from suleptanate has no apparent intrinsic activity.
the intramuscular injection site. The model independent pharmacodynamic measures of Integrated pharmacokinetic and pharmacodynamic analysis for WBH showed no significant differences in the extent of whole blood histamine response (AUEC) or the maximum response (E max ). This was confirmed by the pharmacokinetic-pharmacodynamic The sigmoid Emax model has been compared with other model. Furthermore this model predicts that at plasma pharmacodynamic models for describing WBH data [7, 8] , concentrations of methylprednisolone above the EC 50 value these authors found that a direct suppression model was a even quite large changes in C max would not result in a suitable alternative model. The principal advantage with the significantly greater pharmacodynamic response. In this direct suppression model is that it is better able to study a 250 mg (MP equivalent) i.m. dose of MP suleptanate simultaneously describe data from a range of doses of and MP succinate produced significant differences in C max methylprednisolone [7] . The sigmoid Emax model, linked but this was not translated into a significant difference in to an effect compartment, also fitted the data well and has Emax. This supports the concept that for MP suleptanate been used by others [13] for similar examples. One objection and MP succinate the pharmacodynamic parameters should to this model is that k e0 may not be physiologically be taken into account when assessing bioequivalence rather appropriate, since the hysteresis in the plasma concentrationthan reaching conclusions based on pharmacokinetic data effect curve could be due to the migration rate of the alone. This was further supported by a lack of a significant basophils. However, good fits for the sigmoid E max model difference between the prodrugs in the maximum pharmacowere found for all subjects (Figure 4) . dynamic responses seen for glucose and various blood cell There was a significant difference of 6 h (k e0 , half-life) in count changes. the parameter of the pharmacokinetic link model (Table 4) .
MP suleptanate appears to be a suitable pharmaceutical This was greater than expected based on differences in the alternative to MP succinate when given as an intramuscular pharmacokinetic parameters for MP or the prodrugs (Tables  injection and a pharmacodynamic or PK/PD approach is a 1 and 2). The k e0 parameter accounts for the temporal useful technique for investigating this type of comparative differences in drug levels in plasma and the PD effects. bioavailability issue. Although the plasma concentration profiles for MP are different for the two prodrugs (C max , t max and observed
The authors acknowledge the valuable assistance of the staff terminal half-life) the corresponding value of k e0 should be of the Upjohn Research Clinics-Jasper, Kalamazoo, MI, a function of methylprednisolone pharmacokinetics and not USA. vary significantly between the prodrugs. However, in this example the temporal differences in the MP plasma profiles for the two prodrugs is due to them being different chemical 
